Vertex Updates Its Type 1 Diabetes Stem Cell Programs: One Paused, One Moving Forward

Vertex Pharmaceuticals announced changes to its stem cell therapy trials for Type 1 diabetes in April 2025. While one candidate was discontinued, another continues toward potential regulatory review.

News report, corroborated with 1 indexed study

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Vertex discontinued development of VX-264, an encapsulated islet cell therapy, after it failed to produce enough insulin in clinical trials despite being safe and well-tolerated.
VX-880, now renamed zimislecel, remains in active development and is on track for regulatory submission.
Both programs aim to replace destroyed beta cells with insulin-producing cells derived from stem cells, potentially reducing or eliminating the need for external insulin for extended periods.
C-peptide levels—a measure of natural insulin production—are the current standard for evaluating whether transplanted cells are working effectively.

Understanding Stem Cell Therapy for Type 1 Diabetes

A significant area of Type 1 diabetes research focuses on stem cell-based therapies. The concept is straightforward: scientists grow insulin-producing cells from stem cells in the laboratory, then transplant them into people with Type 1 diabetes to replace the beta cells destroyed by the immune system. If successful, this approach could allow patients to produce insulin again, potentially reducing or eliminating the need for insulin injections, pens, or pumps for months or even years.

Vertex Pharmaceuticals has been testing two different stem cell therapy approaches through clinical trials. Both programs represent years of research and investment aimed at offering Type 1 diabetes patients a fundamentally different treatment option.

VX-264: What Happened and Why It Stopped

On April 3, 2025, Vertex announced that it would not continue development of VX-264, an encapsulated islet cell therapy. This decision came after careful review of trial data.

VX-264 was designed with a special advantage: the insulin-producing cells were placed inside a protective device before implantation, which meant patients would not need to take immunosuppressive drugs that suppress the immune system. In clinical testing, the therapy was safe and well-tolerated—meaning patients did not experience serious side effects.

However, the implanted cells did not produce enough insulin to meet the trial's efficacy goals. Scientists measure insulin production using a marker called C-peptide, which reflects how much insulin the body is making naturally. VX-264 did not raise C-peptide levels sufficiently to justify moving forward with further development.

Vertex continues to analyze the protective devices used in this trial. Those findings may help researchers design better approaches in the future.

VX-880 (Now Zimislecel): The Continuing Trial

While VX-264 was discontinued, Vertex's other stem cell therapy program is advancing. VX-880 has been renamed zimislecel and remains in active clinical development.

The FORWARD trial for zimislecel is continuing as planned, with regulatory submission expected to move forward. This represents Vertex's ongoing commitment to bringing a stem cell-based therapy to people with Type 1 diabetes.

What This Means for the Field

Setbacks in clinical trials are a normal part of developing new medicines. VX-264's discontinuation shows that even therapies that are safe may not work effectively enough to help patients, and companies make the responsible choice to refocus efforts.

At the same time, zimislecel's continued progress demonstrates that stem cell therapy for Type 1 diabetes remains a promising avenue of research. Patients and families interested in these developments should continue following updates from Vertex and consult with their healthcare providers about any trials or treatments being studied in their area.

Evidence label

Origin: breakthrought1d.ca (News report). Evidence: News report, corroborated with 1 indexed study. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.